Clinical trialNCT06090227RecruitingPhase 1/PHASE2Interventional

AMPK-activation by Metformin in FSGS: AMP-FSGS

SponsorYale UniversityEnrollment30Focal Segmental Glomerulosclerosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Cijiang He
Icahn School of Medicine at Mount Sinai
Principal Investigator
clinicaltrials.gov ↗
Madhav Menon, MD
Yale University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Yale New Haven Hospital
New Haven, Connecticut, United States
Francis P Wilson, MDRandy Luciano, MD PhD
Recruiting
Mount Sinai Hospital
New York, New York, United States
Jia FuJoji TokitaKristin Meliambro
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Metformin + Standard of Care

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Dec 2023
Primary completion: 30 Nov 2027
Completion: 30 Nov 2027
Last update posted: 3 Feb 2026
Registered enrollment: 30
Registry id: NCT06090227

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.